Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus hormonal therapy versus hormonal therapy alone as adjuvant treatment in intermediate or high-risk prostate cancer after radical radiotherapy
2006-001657-94Phase 3Completed
- Start
- Oct 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of docetaxel in prostate cancer (PCa) (2 arms). Primary endpoint: Time to PSA progression. Started Oct 2006; status: completed.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-001657-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001657-94.